Project Grant R43HL172516
Award Date
9/20/24
Completion Date
3/14/25
Dollars Obligated
$356K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $834,840 to Brigham & Women's Hospital to conduct research on emulating hypothetical target trials to establish the comparative effectiveness of biologics in treating severe asthma. The research aims to optimize the use of expensive monoclonal antibody biologics for patients with severe asthma who are eligible for multiple...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,806 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to Elimu Informatics Inc., a small business software company in California. The grant funds the design, development, and evaluation of TIBSA (Tailored Interoperable Guideline-Based Clinical Decision-Support System for Asthma), a clinical decision support application that incorporates the 2020 NHLBI asthma management guidelines, patient-specific data,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $740,709 to the University of Utah to conduct research on how early-life viral infections can lead to the development of childhood asthma. The key objectives are to define the cellular and molecular mechanisms by which viral-induced inflammation programs hyperactivated type 2 innate lymphoid cells (ILC2s) in the lung, and determine if these hyperactivated ILC2s...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $636,843 to The Regents of the University of California, San Francisco (UCSF) to conduct research on targeting the stromal niche for tissue-resident lymphocytes in asthma. The research aims to characterize a targetable stromal factor that alters immune cell accumulation in the lung and define the downstream effects on airway epithelial...
This federal Project Grant award for $2,016,357 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Mayo Clinic to investigate the role of Transmembrane Protein 178 (TMEM178) as a novel endogenous inhibitory mechanism in asthma. The research aims to characterize how TMEM178 regulates calcium responses and inflammation in bronchial epithelial cells, and assess the impact of TMEM178 genetic variants on asthma severity. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $777,497.00 to The Washington University to study how the circadian clock mediates the adult age, pro-resolution response to viral asthma triggers. The research aims to clarify how the circadian clock operating within alveolar macrophages and airway epithelial cells promotes the resolution of viral inflammation and normal repair...
This $177,403 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports research to disentangle the heterogeneity of asthma, identify distinct asthma endotypes, and investigate biological mechanisms underlying established risk factors. The project will utilize multi-omics data from three cohorts of asthmatic children to analyze the interplay between genetic, epigenetic, and metabolomic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $320,863 to Aaiit LLC (Inflammation Immuno Therapy) to develop a bifunctional IgE antagonist and dissociator (ANDI) drug to treat severe allergic asthma. The ANDI drug aims to directly access and dissociate IgE bound to mast cell receptors, in contrast to the first-generation Xolair drug which only...